Wooyeol Baek

Dr. Wooyeol Baek

Yonsei University College of Medicine
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJung Bok Lee
Jung Bok Lee
DKDae-Hyun Kim
Dae-Hyun Kim
JYJeong-Kee Yoon
Jeong-Kee Yoon
DPDan Bi Park
Dan Bi Park
HKHye-Seon Kim
Hye-Seon Kim
Hak-Joon SungHak-Joon Sung
Hak-Joon Sung
Angiogenesis induction into damaged sites has long been an unresolved issue. Local treatment with pro-angiogenic molecules has been the most common approach. However, this approach has critical side effects including inflammatory coupling, tumorous vascular activation, and off-target circulation. Here, the concept that a structure can guide desirable biological function is applied to physically engineer three-dimensional channel networks in implant sites, without any therapeutic treatment. Microchannel networks are generated in a gelatin hydrogel to overcome the diffusion limit of nutrients and oxygen three-dimensionally. Hydrogel implantation in mouse and porcine models of hindlimb ischemia rescues severely damaged tissues by the ingrowth of neighboring host vessels with microchannel perfusion. This effect is guided by microchannel size-specific regenerative macrophage polarization with the consequent functional recovery of endothelial cells. Multiple-site implantation reveals hypoxia and neighboring vessels as major causative factors of the beneficial function. This technique may contribute to the development of therapeutics for hypoxia/inflammatory-related diseases.

28 February 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
MKMi-Lan Kang
Mi-Lan Kang
HKHye-Seon Kim
Hye-Seon Kim
JYJin You
Jin You
YCYoung SiK Choi
Young SiK Choi
BKByeong-Ju Kwon
Byeong-Ju Kwon
Hak-Joon SungHak-Joon Sung
Hak-Joon Sung
HMSC source-specific behaviors in 3D NO gel represent EC-like differentiation of ADSCs and pericyte-like characteristics of BMSCs.

1 November 2014 in Archives of Plastic Surgery
Verified
Journal Article
Open access
PDF file
Wooyeol BaekWooyeol Baek
Wooyeol Baek
DLDae Hyun Lew
Dae Hyun Lew
DLDong Won Lee
Dong Won Lee
Background Rupture is an important complication of breast implants. Before cohesive gel silicone implants, rupture rates of both saline and silicone breast implants were over 10%. Through an analysis of ruptured implants, we can determine the various factors related to ruptured implants. Methods We performed a retrospective review of 72 implants that were removed for implant rupture between 2005 and 2014 at a single institution. The following data were collected: type of implants (saline or silicone), duration of implantation, type of implant shell, degree of capsular contracture, associated symptoms, cause of rupture, diagnostic tools, and management. Results Forty-five Saline implants and 27 silicone implants were used. Rupture was diagnosed at a mean of 5.6 and 12 years after insertion of saline and silicone implants, respectively. There was no association between shell type and risk of rupture. Spontaneous was the most common reason for the rupture. Rupture management was implant change (39 case), microfat graft (2 case), removal only (14 case), and follow-up loss (17 case). Conclusions Saline implants have a shorter average duration of rupture, but diagnosis is easier and safer, leading to fewer complications. Previous-generation silicone implants required frequent follow-up observation, and it is recommended that they be changed to a cohesive gel implant before hidden rupture occurs.

23 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
HCHee Jin Cho
Hee Jin Cho
KYKum-Hee Yun
Kum-Hee Yun
SSSu-Jin Shin
Su-Jin Shin
YLYoung Han Lee
Young Han Lee
SKSeung Hyun Kim
Seung Hyun Kim
HKHyo Song Kim
Hyo Song Kim
We aimed to determine the activity of the anti-VEGF receptor tyrosine-kinase inhibitor, pazopanib, combined with the anti-PD-L1 inhibitor, durvalumab, in metastatic and/or recurrent soft tissue sarcoma (STS). In this single-arm phase 2 trial (NCT03798106), treatment consisted of pazopanib 800 mg orally once a day and durvalumab 1500 mg once every 3 weeks. Primary outcome was overall response rate (ORR) and secondary outcomes included progression-free survival (PFS), overall survival, disease control rate, immune-related response criteria, and safety. The ORR was 30.4% and the trial met the pre-specified endpoint. The median PFS was 7.7 months (95% confidence interval: 5.7–10.4). The common treatment-related adverse events of grades 3–4 included neutropenia (9 [19.1%]), elevated aspartate aminotransferase (7 [14.9%]), alanine aminotransferase (5 [10.6%]), and thrombocytopenia (4 [8.5%]). In a prespecified transcriptomic analysis, the B lineage signature was a significant key determinant of overall response (P = 0.014). In situ analysis also showed that tumours with high CD20+ B cell infiltration and vessel density had a longer PFS (P = 6.5 × 10−4) than those with low B cell infiltration and vessel density, as well as better response (50% vs 12%, P = 0.019). CD20+ B cell infiltration was identified as the only independent predictor of PFS via multivariate analysis. Durvalumab combined with pazopanib demonstrated promising efficacy in an unselected STS cohort, with a manageable toxicity profile.

8 December 2023 in Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Closed access
PDF file
HJHye-Jeong Jang
Hye-Jeong Jang
KSKyu-Sik Shim
Kyu-Sik Shim
JLJinah Lee
Jinah Lee
JPJoo Hyeon Park
Joo Hyeon Park
SKSeong-Jun Kang
Seong-Jun Kang
JYJeong-Kee Yoon
Jeong-Kee Yoon

16 February 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JAJin-Hee Ahn
Jin-Hee Ahn
JLJeeyun Lee
Jeeyun Lee
CPChanghee Park
Changhee Park
SBSeung-Hoon Beom
Seung-Hoon Beom
SKSeung Hyun Kim
Seung Hyun Kim
HKHyo Song Kim
Hyo Song Kim
Purpose: The study was to determine the activity and safety of the TGF-β inhibitor vactosertib in combination with imatinib in patients with desmoid tumors. Patients and Methods: In this investigator-initiated, open-label, multicenter, phase Ib/II trial, patients with desmoid tumors not amenable to locoregional therapies (surgery and/or radiotherapy) or with disease progression following at least one treatment were enrolled. Participants were administered 400 mg imatinib daily in combination with vactosertib (5 days on and 2 days off, twice a day) every 28 days. In phase Ib, the vactosertib dose was set at 100 mg (level −1) and 200 mg (level 1) to determine the recommended phase II dose (RP2D). Phase II assessed the efficacy, with the primary endpoint being progression-free rate (PFR) at 16 weeks. Results: No dose-limiting toxicities were observed during phase Ib; therefore RP2D was defined at doses of 400 mg imatinib daily in combination with 200 mg vactosertib. Of the 27 patients evaluated, 7 (25.9%) achieved a confirmed partial response and 19 (70.4%) were stable. The PFR at 16 weeks and 1 year were 96.3% and 81.0%, respectively. Most toxicities were mild to moderate myalgia (n = 10, 37%), anemia (n = 10, 37%), and nausea (n = 9, 33.3%). Common grade 3 to 4 toxicities included neutropenia (n = 6, 22.2%) and anemia (n = 5, 18.5%). Conclusions: The vactosertib and imatinib combination was well tolerated, with promising clinical activity in patients with progressive, locally advanced desmoid tumors. This is the first study investigating a novel target agent, a TGF-β inhibitor, in this rare and difficult-to-treat desmoid tumor.